Redefining cardiometabolic health through microbiome innovation
A unique biotechnology platform to fast develop next-generation -biotics that help prevent and manage cardiometabolic disorders through Gut Microbiota.
This proprietary technology combines rapid strain screening, advanced in vivo models, and cutting-edge clinical research and real world evidence to accelerate the development of safe, effective, and stable microbiome-based products.
​
Our first breakthrough pA1c®HI, is the first postbiotic clinically validated for glucose control, offering a natural, effective solution for people with diabetes.
Awards & Support Funds
A strong commitment to innovation and health has been recognised with multiple prestigious awards, reflecting a leading role in the agrifood and metabolic health sectors.
This journey is supported by national and international institutions that fuel the development of cutting-edge, science-based solutions to improve people’s lives.
“Healthy Food" Award at FoodTech Innovation Awards, Food 4 Future ExpoFoodTech 2024
Spain UP Nation’s Top 101 2024
TOP 3 BIOTICS INNOVATION by NutriMarketing, Vitafood Europe 2025
Food for Health Challenge 2024
Premio EmprendeXXI Startup más innovadora en NAVARRA 2023
Premio Emprende Alimentaria FoodTech 2023
Sello Pyme Innovadora 2022
Probiota Pioneers 2022
APTENISA 2022
EIT FUN&FAN AWARD 2021
Our Research Grants
2024 - 2025
Ayudas para la creación y consolidación de empresas innovadoras de base tecnológica (EIBT) 2025
As part of its ongoing commitment to innovation, Genbioma has launched a new R&D initiative supported by the Government of Navarra. This strategic project aims to accelerate the development of advanced postbiotic solutions to improve metabolic health, with a focus on type 2 diabetes, prediabetes, and obesity.
Esta empresa ha recibido una subvención del Gobierno de Navarra al amparo de la convocatoria de 2025 de ayudas a la creación y consolidación de empresas innovadoras de base tecnológica en el marco del Plan deRecuperación, Transformación y Resiliencia - Financiado por la Unión Europea – Next Generation EU.
2023 - 2025
Convocatoria TRANSFERENCIA CONOCIMIENTO GOBIERNO DE NAVARRA 2023
We are excited to announce the launch of the GLUCOPSICOBIOMICS project, funded by the Government of Navarra under the Knowledge Transfer program. This project has received a grant of 281.000 € and is co-financed by the European Regional Development Fund (ERDF) through the 2014-2020 Operational Program of Navarra. The project is a collaboration between Genbioma Aplicaciones SL, UPNA, Fundación Miguel Servet, and MyVitale.
The GLUCOPSICOBIOMICS project aims to develop and evaluate the effectiveness of probiotics and postbiotics in preventing and treating metabolic syndrome in patients. The project will involve preclinical trials using C. elegans and murine models, as well as a clinical trial in Navarra to monitor health improvements and provide personalized nutritional and activity guidelines
2022 -2023
NEOTEC 2021
Estudio de la microbiota intestinal y de la efectividad de probióticos para la mejorar la glucemia a largo plazo.
The NEOTEC 2021 project is centered on advancing business development and formulating a comprehensive strategic business plan. This initiative is supported by a grant of 325,000 € from CDTI and is co-financed by the European Union through the Next Generation EU funds.
The project aims to enhance Genbioma's market presence by identifying new business opportunities and optimizing its operational strategies. It focuses on scaling up the production of their innovative postbiotic ingredients, expanding their market reach, and establishing strategic partnerships. Additionally, the project includes the development of a robust marketing strategy to promote their products and increase brand awareness. This comprehensive approach is designed to ensure sustainable growth and long-term success for Genbioma in the competitive biotechnology sector.
2022 - 2025
PROYECTOS EN COLABORACIÓN PÚBLICO-PRIVADA 2021
Precision Medicine Against Type 2 Diabetes: Genetic Prediction and Nutritional Intervention with Probiotics Modulating the Microbiota
Genbioma launches the CPP2021-008725 project, titled "." This innovative project, funded by the Ministry of Science and Innovation and the European Union through the Next Generation EU funds, aims to develop advanced solutions for managing Type 2 diabetes.
By leveraging genetic prediction and nutritional interventions with probiotics, Genbioma seeks to improve patient outcomes and contribute to the field of precision medicine. The project is a collaborative effort involving Genbioma, the Biocruces Bizkaia Health Research Institute, the University of Navarra, and Patia. The total funding for this project is €1,700,000.
2023
Programa EUROPA + CERCA 2023
Genbioma Aplicaciones SL receives aid from the call "PROGRAMA EUROPA + CERCA 2023." This aid aims to provide subsidies for the participation in European projects. The initiative seeks to strengthen the capacity of organizations to engage in European projects by facilitating the incorporation of specialized personnel and resources. Funded by the Government of Navarra.
2023
Ayudas a la contratación de personas promotoras y gestoras de proyectos europeos 2023
Aid from the call "Grants for the hiring of promoters and managers of European projects" for the year 2023. This aid aims to provide subsidies for the hiring of individuals who will promote and manage European projects. The initiative seeks to strengthen the capacity of organizations to participate in European projects by facilitating the incorporation of specialized personnel in the promotion and management of such projects. The aid is provided by the Government of Navarra and amounts to 15.000 €.
2021 - 2022
TRANSFERENCIA CONOCIMIENTO GOBIERNO DE NAVARRA 2020
Funded by the Government of Navarra under the Knowledge Transfer program. This project has received a grant of €416,000 and is co-financed by the European Regional Development Fund (ERDF) through the 2021-2027 Operational Program of Navarra.
The project aims to develop nutritional formulas for prediabetic populations based on microorganisms with normoglycemic capabilities. The goal is to create a new nutritional supplement incorporating a bacterial strain with a differential normoglycemic effect, targeting prediabetic individuals. The project is a collaboration between Genbioma Aplicaciones SL, UPNA, and CIN-UNAV.